bluuebunny/crossref_metadata_2025_split huggingface dataset:
Fruit development of the diploid kiwifruit, Actinidia chinensis 'Hort16A'
Authors: Richardson Annette C , Boldingh Helen L , McAtee Peter A , Gunaseelan Kularajathevan , Luo Zhiwei , Atkinson Ross G , David Karine M , Burdon Jeremy N , Schaffer Robert J 
Published: December 2011

AbstractBackgroundWith the advent of high throughput genomic tools, it is now possible to undertake detailed molecular studies of individual species outside traditional model organisms. Combined with a good understanding of physiological processes, these tools allow researchers to explore natural diversity, giving a better understanding of biological mechanisms. Here a detailed study of fruit development from anthesis through to fruit senescence is presented for a non-model organism, kiwifruit,Actinidia chinensis('Hort16A').ResultsConsistent with previous studies, it was found that many aspects of fruit morphology, growth and development are similar to those of the model fruit tomato, except for a striking difference in fruit ripening progression. The early stages of fruit ripening occur as the fruit is still growing, and many ripening events are not associated with autocatalytic ethylene production (historically associated with respiratory climacteric). Autocatalytic ethylene is produced late in the ripening process as the fruit begins to senesce.ConclusionBy aligningA. chinensisfruit development to a phenological scale, this study provides a reference framework for subsequent physiological and genomic studies, and will allow cross comparison across fruit species, leading to a greater understanding of the diversity of fruits found across the plant kingdom.
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events
Authors: Kim Hani , Gillis Lisa C , Jarvis Jordan D , Yang Stuart , Huang Kai , Der Sandy , Barber Dwayne L 
Published: December 2011

AbstractBackgroundLeukemia is a heterogeneous disease commonly associated with recurrent chromosomal translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the activated tyrosine kinases have focused on proximal signaling events, but little is known about gene transcription regulated by these fusions.MethodsOligonucleotide microarray was performed to compare mRNA changes attributable to BCR-ABL, TEL-PDGFRB and TEL-JAK2 after 1 week of activation of each fusion in Ba/F3 cell lines. Imatinib was used to control the activation of BCR-ABL and TEL-PDGFRB, and TEL-JAK2-mediated gene expression was examined 1 week after Ba/F3-TEL-JAK2 cells were switched to factor-independent conditions.ResultsMicroarray analysis revealed between 800 to 2000 genes induced or suppressed by two-fold or greater by each tyrosine kinase, with a subset of these genes commonly induced or suppressed among the three fusions. Validation by Quantitative PCR confirmed that eight genes (Dok2, Mrvi1, Isg20, Id1, gp49b, Cxcl10, Scinderin, and collagen Vα1(Col5a1)) displayed an overlapping regulation among the three tested fusion proteins. Stat1 and Gbp1 were induced uniquely by TEL-PDGFRB.ConclusionsOur results suggest that BCR-ABL, TEL-PDGFRB and TEL-JAK2 regulate distinct and overlapping gene transcription profiles. Many of the genes identified are known to be involved in processes associated with leukemogenesis, including cell migration, proliferation and differentiation. This study offers the basis for further work that could lead to an understanding of the specificity of diseases caused by these three chromosomal translocations.
Comparative one-factor-at-a-time, response surface (statistical) and bench-scale bioreactor level optimization of thermoalkaline protease production from a psychrotrophic Pseudomonas putida SKG-1 isolate
Authors: Singh Santosh K , Singh Sanjay K , Tripathi Vinayak R , Khare Sunil K , Garg Satyendra K 
Published: December 2011

Abstract

Background
Production of alkaline protease from various bacterial strains using statistical methods is customary now-a-days. The present work is first attempt for the production optimization of a solvent stable thermoalkaline protease by a psychrotrophic Pseudomonas putida isolate using conventional, response surface methods, and fermentor level optimization.

Results
The pre-screening medium amended with optimized (w/v) 1.0% glucose, 2.0% gelatin and 0.5% yeast extract, produced 278 U protease ml-1 at 72 h incubation. Enzyme production increased to 431 Uml-1 when Mg2+ (0.01%, w/v) was supplemented. Optimization of physical factors further enhanced protease to 514 Uml-1 at pH 9.0, 25°C and 200 rpm within 60 h. The combined effect of conventionally optimized variables (glucose, yeast extract, MgSO4 and pH), thereafter predicted by response surface methodology yielded 617 U protease ml-1 at glucose 1.25% (w/v), yeast extract 0.5% (w/v), MgSO4 0.01% (w/v) and pH 8.8. Bench-scale bioreactor level optimization resulted in enhanced production of 882 U protease ml-1 at 0.8 vvm aeration and 150 rpm agitation during only 48 h incubation.

Conclusions
The optimization of fermentation variables using conventional, statistical approaches and aeration/agitation at fermentor level resulted in ~13.5 folds increase (882 Uml-1) in protease production compared to un-optimized conditions (65 Uml-1). This is the highest level of thermoalkaline protease reported so far by any psychrotrophic bacterium.
Tracheo-brachiocephalic artery fistula after tracheostomy associated with thoracic deformity: a case report
Authors: Ogawa Kie , Nitta Norihisa , Sonoda Akinaga , Takahashi Masashi , Suzuki Tomoaki , Kitamura Shoji , Hanaoka Jun , Tezuka Noriaki , Murata Kiyoshi 
Published: December 2011

Abstract

Introduction
Tracheo-brachiocephalic artery fistulae are critical long-term complications after tracheostomy, reported in 0.6% of patients within three to four weeks after the procedure. In 30% to 50% of cases there is some bleeding prior to onset. Since the onset involves sudden massive bleeding, the prognosis is poor; the reported survival rate is 10% to 30%. The direct cause of bleeding is the formation of a fistula with the trachea subsequent to arterial injury by the tracheostomy tube. Endo-tracheal factors are movement of the tracheostomy tube due to body movement and seizures, pressure exerted by the cuff of the tracheostomy tube, tracheostomy at lower levels, and the fragility of blood vessels and the trachea due to steroid or radiation therapy, and malnutrition. Extra-tracheal factors include prior surgery and deformity and shifting of the trachea and major blood vessels due to congenital kyphoscoliosis or thoracic deformity. There has been no report of the usefulness of contrast-enhanced computed tomography studies to identify the anatomical relationship between the trachea and brachiocephalic artery.

Case presentation
A 27-year-old Mongolian woman with congenital muscular dystrophy who underwent tracheal intubation for airway management due to pneumonia and granulation development developed a tracheo-brachiocephalic artery fistula during the placement of the tracheostomy tube. It was diagnosed by contrast-enhanced chest computed tomography and repaired. About a month later she developed massive airway bleeding during replacement of the tracheostomy tube. Temporary hemostasis was achieved by compression via cuff inflation. A contrast-enhanced chest computed tomography scan demonstrated a narrowed brachiocephalic artery running along and ventral to the tube and a tracheo-brachiocephalic artery fistula was suspected. She underwent brachiocephalic artery resection and aorta, right common carotid artery, and subclavian artery bypass surgery with an innominate vein, tracheoplasty, and partial sternectomy. We noted marked thoracic deformity; the brachiocephalic artery was compressed by the trachea and chest wall resulting in localized wall necrosis and the development of a tracheo-brachiocephalic artery fistula, a fatal complication whose prevention is important.

Conclusions
We suggest that before tracheostomy, the anatomic relationship between the trachea and brachiocephalic artery must be confirmed by contrast-enhanced chest computed tomography scan.
Blood lactate as a predictor for in-hospital mortality in patients admitted acutely to hospital: a systematic review
Authors: Kruse Ole , Grunnet Niels , Barfod Charlotte 
Published: December 2011

Abstract

Background
Using blood lactate monitoring for risk assessment in the critically ill patient remains controversial. Some of the discrepancy is due to uncertainty regarding the appropriate reference interval, and whether to perform a single lactate measurement as a screening method at admission to the hospital, or serial lactate measurements. Furthermore there is no consensus whether the sample should be drawn from arterial, peripheral venous, or capillary blood. The aim of this review was:
1) To examine whether blood lactate levels are predictive for in-hospital mortality in patients in the acute setting, i.e. patients assessed pre-hospitally, in the trauma centre, emergency department, or intensive care unit.
2) To examine the agreement between arterial, peripheral venous, and capillary blood lactate levels in patients in the acute setting.

Methods
We performed a systematic search using PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL up to April 2011. 66 articles were considered potentially relevant and evaluated in full text, of these ultimately 33 articles were selected.

Results and Conclusion
The literature reviewed supported blood lactate monitoring as being useful for risk assessment in patients admitted acutely to hospital, and especially the trend, achieved by serial lactate sampling, is valuable in predicting in-hospital mortality. All patients with a lactate at admission above 2.5 mM should be closely monitored for signs of deterioration, but patients with even lower lactate levels should be considered for serial lactate monitoring. The correlation between lactate levels in arterial and venous blood was found to be acceptable, and venous sampling should therefore be encouraged, as the risk and inconvenience for this procedure is minimal for the patient. The relevance of lactate guided therapy has to be supported by more studies.
Uptake of prevention of mother to child transmission interventions in Kenya: health systems are more influential than stigma
Authors: Kinuthia John , Kiarie James N , Farquhar Carey , Richardson Barbra A , Nduati Ruth , Mbori‐Ngacha Dorothy , John‐Stewart Grace 
Published: December 2011

BackgroundWe set out to determine the relative roles of stigma versus health systems in non‐uptake of prevention of mother to child transmission (PMTCT) of HIV‐1 interventions: we conducted cross‐sectional assessment of all consenting mothers accompanying infants for six‐week immunizations.MethodsBetween September 2008 and March 2009, mothers at six maternal and child health clinics in Kenya's Nairobi and Nyanza provinces were interviewed regarding PMTCT intervention uptake during recent pregnancy. Stigma was ascertained using a previously published standardized questionnaire and infant HIV‐1 status determined by HIV‐1 polymerase chain reaction.ResultsAmong 2663 mothers, 2453 (92.1%) reported antenatal HIV‐1 testing. Untested mothers were more likely to have less than secondary education (85.2% vs. 74.9%, p = 0.001), be from Nyanza (47.1% vs. 32.2%, p < 0.001) and have lower socio‐economic status. Among 318 HIV‐1‐infected mothers, 90% reported use of maternal or infant antiretrovirals. Facility delivery was less common among HIV‐1‐infected mothers (69% vs. 76%, p = 0.009) and was associated with antiretroviral use (p < 0.001). Although internal or external stigma indicators were reported by between 12% and 59% of women, stigma was not associated with lower HIV‐1 testing or infant HIV‐1 infection rates; internal stigma was associated with modestly decreased antiretroviral uptake. Health system factors contributed to about 60% of non‐testing among mothers who attended antenatal clinics and to missed opportunities in offering antiretrovirals and utilization of facility delivery. Eight percent of six‐week‐old HIV‐1‐exposed infants were HIV‐1 infected.ConclusionsAntenatal HIV‐1 testing and antiretroviral uptake was high (both more than 90%) and infant HIV‐1 infection risk was low, reflecting high PMTCT coverage. Investment in health systems to deliver HIV‐1 testing and antiretrovirals can effectively prevent infant HIV‐1 infection despite substantial HIV‐1 stigma.
Effect of the Accountable Care Act of 2010 on Clinical Trial Insurance Coverage
Authors: Kircher Sheetal M. , Benson Al B. , Farber Matthew , Nimeiri Halla S. 
Published: December 2011

Purpose The Affordable Care Act (ACA) of 2010 implemented dramatic changes in our health care system. The new law requires that insurers and health plans provide coverage for individuals participating in clinical trials. Currently, there are states that already have laws or agreements requiring clinical trial coverage, but there remain deficiencies that will need to be addressed to achieve compliance with the new law. Methods State mandates were reviewed to determine current laws and agreements. The ACA was reviewed to outline its provisions, and these were compared with current mandates to identify deficiencies. Results Eighteen states meet the requirements set forth by the ACA either through a state law or agreement; 33 states do not meet the requirements. Of these 33 states, 15 do not have any existing laws or agreements in place regarding clinical trials. In states that have deficient policies in place, the most common deficiency is the lack of phase I coverage. The second most common deficiency in policy is coverage of only therapeutic studies. Conclusion Most states currently do not meet the requirements of the ACA and will be required to make changes by 2014. The implications of the ACA with regard to insurance coverage of clinical trials remain unclear as implementation of the legislation unfolds. State governments can take steps to ensure insurance coverage by creating and expanding agreements with insurance companies.
Design, Optimization and Analysis of Hydraulic Soft Yaw System for 5 MW Wind Turbine
Authors: Stubkier Søren , Pedersen Henrik C. 
Published: December 2011

As wind turbines increase in size and the demands for lifetime also increases, new methods of load reduction needs to be examined. One method is to make the yaw system of the turbine soft/flexible and hence dampen the loads to the system, which is the focus of the current paper. The paper first presents work previous done on this subject with focus on hydraulic yaw systems. By utilizing the HAWC2 aeroelastic code and an extended model of the NREL 5MW turbine combined with a simplified linear model of the turbine, the parameters of the soft yaw system are optimized. Results show that a significant reduction in fatigue and extreme loads to the yaw system and rotor shaft are possible, when utilizing the soft yaw drive concept compared to the original stiff yaw system. The physical demands of the hydraulic yaw system are furthermore examined for a life time of 20 years. The duty cycles, based on the extrapolated loads, show that it is possible to construct a hydraulic soft yaw system, which is able to reduce the loads on the wind turbine significantly.
Formulation of an Operation Theory for Wind-Generators with Controlled Variable Speed-Ratio
Authors: Siddig Mohammed Hashim 
Published: December 2011

The basic variables relevant to wind generation systems were formulated in this study as to relate the operational torque coefficient to the power output and wind velocity. A dimensionless number connecting wind velocity, power output, generator speed, turbine size and air density was identified and shown to be the pivotal independent parameter of the wind-generator operation. An optimization criterion based on this mathematical formulation was developed. It relates the gearbox's speed-ratio to the newly defined wind generator number. This led, in turn, to the introduction of a variable speed-ratio gearbox that has a constant speed output and a variable turbine shaft-speed to be controlled in such a way as to match continuously and optimally the operation condition. Making use of a reported experimental study of a variable pitch-angle turbine driving an induction generator, a demonstration of the design procedure was presented. The model was shown to accurately predict the experimentally produced results. The demonstration proceeded to predict the optimum performance for the reported system.
Warfarin for Venous Thromboembolism Prophylaxis After Elective Hip or Knee Arthroplasty: Exploring the Evidence, Guidelines, and Challenges Remaining
Authors: Dager William E 
Published: December 2011

BACKGROUND: Guidelines for the prevention of venous thromboembolism (VTE) after elective total hip or knee arthroplasty (THA/TKA) have been developed separately by the American Academy of Orthopaedic Surgeons (AAOS) and the American College of Chest Physicians (ACCP). Differences exist in approaches to preventing postoperative VTE through prophylaxis. OBJECTIVE: To compare trials using vitamin K antagonists (VKAs) and differences in guidelines to determine the benefits and drawbacks of warfarin for VTE prophylaxis following THA/TKA. DATA SOURCES: Guidelines from the AAOS published in 2009 and revised in 2011 and from the ACCP published in 2008 were compared for recommendations on the use of VKAs. A MEDLINE search from 1960 to November 2009 was conducted to identify pertinent articles on the use of warfarin or VKAs for VTE prophylaxis following THA/TKA. Search terms included warfarin, vitamin K antagonist, total hip or total knee replacement, and total hip or total knee arthroplasty. STUDY SELECTION AND DATA EXTRACTION: Only clinical trials in which warfarin was the primary agent for prophylaxis compared to other anticoagulants were included. DATA SYNTHESIS: Data on differences between guideline recommendations for the use of VKAs and the importance of a deep vein thrombosis or asymptomatic events were extracted. Thirteen comparative trials using VKAs for VTE prophylaxis and international normalized ratio (INR) targets were assessed. Overall, the incidence of bleeding tended to be lower with the use of VKAs, but thrombosis when including asymptomatic events was numerically higher when comparing INR targets. However, INR targets varied, with no comparative trials assessing the AAOS 2009 recommended INR target of 1.5-2.0. The AAOS guidelines initially recommended a longer duration of therapy and expressed stronger support for the use of aspirin for prophylaxis; however, in 2011, its guidelines were revised, with no specific recommendations as to agent, dose, or INR target goal. CONCLUSIONS: Warfarin is an effective agent to prevent VTE after elective THA/TKA. The most effective approach, including extended warfarin use up to 4 weeks or longer, has not been determined.
Lung Transplantation Across Donor-Specific Anti-Human Leukocyte Antigen Antibodies: Utility of Bortezomib Therapy in Early Graft Dysfunction
Authors: Stuckey Linda J , Kamoun Malek , Chan Kevin M 
Published: December 2011

OBJECTIVE: To report the usefulness of bortezomib therapy in a sensitized lung transplant recipient experiencing antibody-mediated rejection. CASE SUMMARY: During a pretransplant evaluation, a 62-year-old woman with usual interstitial pneumonitis developed a diverticular bleed requiring transfusions, which elevated her panel reactive antibody to 98% for human leukocyte antigen (HLA) class I and 71% for class II. She underwent desensitization to decrease her panel reactive antibody levels. She received a double lung transplant across a weak HLA class II incompatibility but developed respiratory failure due to early graft dysfunction. On postoperative day (POD) 14 she was found to have donor-specific antibodies (DSA) to HLA class I and class II antigens. She received intravenous immunoglobulin (IVIG), plasmapheresis, and bortezomib to reduce the DSA. Repeat DSA testing on POD 80 demonstrated a 50% reduction in DSA, which became undetectable at POD 255. DISCUSSION: Antibody-mediated rejection (AMR) is difficult to diagnose and treat in lung transplantation. Since primary treatment options such as plasmapheresis and IVIG alone may not adequately eradicate DSA, the proteasome inhibitor bortezomib can be of additional value for the treatment of AMR. Bortezomib causes apoptosis of plasma cells, thus eliminating the production of allograftspecific DSA. CONCLUSIONS: This is the first report describing the utility of bortezomib for early graft dysfunction in a highly sensitized lung transplant recipient. Although this patient had preformed donor-specific anti-HLA antibodies, AMR was successfully treated with a combination of plasmapheresis, IVIG, and bortezomib. At time of writing, the patient continued to have excellent graft function 2 years posttransplant. Bortezomib is a potent inhibitor of plasma cell production and it appears to be useful for the treatment of antibody-mediated graft dysfunction.
Glycemic Control and Preventive Care Measures of Indigent Diabetes Patients Within a Pharmacist-Managed Insulin Titration Program vs Standard Care
Authors: Salvo Marissa C , Brooks Amie McCord 
Published: December 2011

BACKGROUND: Studies assessing pharmacist-led services have noted positive clinical diabetes outcomes; however, studies assessing pharmacist impact on glycemic control through insulin titration and adherence to American Diabetes Association (ADA) preventive care measures in an indigent population are limited. OBJECTIVE: To assess the impact of a pharmacist-managed insulin titration program compared to standard medical care on glycemic control and preventive care measures in an indigent population with diabetes. METHODS: This retrospective cohort study compared pharmacist-managed insulin titration to standard care; all patients received primary care services through a county-funded health center serving a low-income minority population. The pharmacist-managed patients, referred by the primary care provider, received telephone calls to assess blood glucose levels, encourage preventive care examinations, and titrate insulin doses through collaborative drug therapy management. Standard care patients received diabetes care solely from the primary care provider. Student t test was used to evaluate the primary outcome, glycemic control, assessed by change in hemoglobin A1c (A1C) between groups from baseline to various time points and study end. Secondary outcomes included attainment of preventive care measures and A1C goal of less than 7% and change in weight and total daily insulin dose from baseline to study end. RESULTS: Sixty-nine patients in the pharmacist-managed group (intervention) and 57 standard care patients (control) were evaluated. The pharmacist-managed group showed a significant difference in A1C at all time points, including, study end, compared to standard care (−1.3% vs −0.18%, respectively; p = 0.001). In addition, the intervention group more often completed the ADA's recommended preventive care measures; all differences were statistically significant. CONCLUSIONS: Pharmacist-provider collaboration can result in significant clinical improvements, including A1C reduction and adherence to preventive care measures, when compared to standard care in a medically underserved population with diabetes.